<unk>  is an experimental combination drug formulation of<unk> , a μ-opioid receptor (MOR) weak partial agonist and κ-opioid receptor (KOR) antagonist, and naltrexone, a MOR and KOR silent antagonist, which is under investigation for the potential treatment of psychiatric disorders. The combination of the two drugs is thought to result in a selective blockade of the KOR and hence fewer MOR activation-related concerns such as euphoria and opioid dependence. It has been found to produce antidepressant-like effects in mice (similarly to the case of<unk>  alone or in combination with samidorphan) and (at a<unk>  dosage of 16 mg/day but not 4 mg/day) has recently been found to be effective in the treatment of cocaine dependence in a large clinical trial.
Buprenorphine/naltrexone
Buprenorphine/naloxone
Buprenorphine/samidorphan
Oxycodone/naloxone
Tranylcypromine/trifluoperazine
Methadone
Naltrexone/bupropion
Isomethadone